Astrotech reports Q1 FY2023 revenue of $38K, authorizes $1M share repurchase

ASTROTECH Corp

Revenue $38K for Q1 FY2023, down from prior year due to shift from ETD to AgLAB-1000-D2 commercialization.
Cash and liquid investments total $48.9M, supporting R&D, organic growth, and potential acquisitions.
Board authorized $1M share repurchase program from Nov 17, 2022 through Nov 17, 2023.
BreathTech subsidiary contracts clinical research firm to collect breath samples; BreathTest-1000 shows discrimination ability.
AgLAB-1000-D2 field trials promising; first production run started and sales efforts underway.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ASTROTECH Corp reported first quarter of fiscal year 2023, which ended September 30, 2022 results: revenue $38 thousand.

Period: first quarter of fiscal year 2023, which ended September 30, 2022
Revenue: $38 thousand
Result: reported results

Exact text from the filing

Revenue for the quarter totaled $38 thousand and was mainly related to ongoing maintenance services and sales of consumables for the TRACER 1000TM explosive trace detector (ETD).

View on SEC.gov

Browse all earnings releases →

ASTROTECH Corp filing history →

Source: SEC EDGAR

accession 0001437749-22-026776

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.